TIDMMEDG 
 
RNS Number : 2692N 
Medgenics Inc 
09 June 2010 
 
 
 
 
                  MEDGENICS ENHANCES STRATEGIC ADVISORY BOARD 
 
Misgav, Israel and London, UK -9 June 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), 
the company that has developed a novel technology for the manufacture and 
delivery of therapeutic proteins continuously in patients using their own 
tissue, announces  the addition of a highly experienced Pharmaceutical 
Executive, Mr. Burt Rosen, to its Strategic Advisory Board. As the Company 
further develops its technology platform, a competency in dealing with the 
regulatory and reimbursement issues becomes highly desirable.  As a result, the 
Company has decided to expand its Scientific Advisory Board to include members 
that possess a wider range of professional and commercial skills that will be 
required for the Company going forward. 
 
Burt Rosen is a serial entrepreneur with over 20 years' experience. Burt has 
developed and implemented Federal, State, and Communications strategies for five 
major pharmaceutical and consumer product companies. Prior to its sale to 
Johnson & Johnson in 2009 for $1.17B, Burt served on the Board of Directors of 
Mentor Corporation, an NYSE listed medical device company.  In his current 
position as Vice President of Federal Government Relations for Purdue 
Pharmaceuticals, Burt's primary responsibilities include providing strategic 
advice and leadership to the senior management of that company, and to act as 
Chairman of its Issues Co-ordinating Team. 
 
Burt has been active in the government relations and communications industries 
since 1978, and has worked for such high profile companies as SmithKline Beecham 
(now GlaxoSmithKline), Bristol-Myers Squibb and Novartis. His duties have ranged 
from developing legislation to identifying potential licensing and strategic 
opportunities. The Board of Directors of Medgenics believes that the addition of 
Burt will provide valuable assistance to the Company as it pursues partnering 
opportunities and seeks regulatory approval, reimbursement from third party 
payers (government and private) and sourcing of advocacy groups. The Board 
further believes that he will be a key asset in strategic planning with 
extensive contacts and many years of experience as a senior executive in the 
pharmaceutical industry. 
 
Commenting on the appointment, Dr Andrew Pearlman, CEO of Medgenics said: 'We 
are delighted by this new appointment and believe that Burt's extensive contacts 
among senior pharmaceutical executives will complement the work of our top team 
leading our business development programme.  In addition, the regulatory and 
lobbying expertise among government and patient advocacy groups will be 
invaluable as we seek to fully commercialise the Medgenics technology.' 
 
 
For further information, contact: 
 
+----------------------------------+--------------------------+ 
| Medgenics, Inc.                  | Phone: +972 4 902 8900   | 
| Dr. Andrew L. Pearlman           |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
| De Facto Communications          | Phone: +44 207 861 3838  | 
| Mike Wort                        |                          | 
| Anna Dunphy                      |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
| Religare Capital Markets (Nomad) | Phone: +44 207 444 0800  | 
| James Pinner                     |                          | 
| Derek Crowhurst                  |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
 
+----------------------------------+--------------------------+ 
| SVS Securities plc (Joint        | Phone: +44 207 638 5600  | 
| Broker)                          |                          | 
| Alex Mattey                      |                          | 
| Ian Callaway                     |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
 
+----------------------------------+--------------------------+ 
| Nomura Code Securities (Joint    | Phone: +44 207 776 1219  | 
| Broker)                          |                          | 
| Jonathan Senior                  |                          | 
|                                  |                          | 
|                                  |                          | 
+----------------------------------+--------------------------+ 
 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUGUQPQUPUGCR
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Medgenics(Regs) Charts.